• Immunocore Holdings recently reported updated Phase 1 results for its TCR bispecific brenetafusp in heavily pretreated HLA-A*02:01-positive advanced melanoma, showing a 6‑month overall survival rate of 87% and a disease control rate of 52%, and confirming 160 mcg as the dose for the ongoing Phase 3 PRISM-MEL-301 trial.
• This early signal of durable disease control in a difficult-to-treat melanoma population highlights how brenetafusp could broaden Immunocore’s oncology franchise beyond KIMMTRAK if later-stage data eventually prove successful.
• We’ll now examine how the selection of a 160 mcg Phase 3 dose for brenetafusp may influence Immunocore’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Immunocore Holdings Investment Narrative Recap

To own Immunocore, you need to believe its TCR platform can turn KIMMTRAK’s success into a broader, multi-drug oncology business before its lead asset matures. The updated Phase 1 brenetafusp data and selection of a 160 mcg dose feed directly into PRISM-MEL-301, which now looks like an even more important near term catalyst, while clinical or regulatory setbacks across the Phase 3 portfolio remain the central risk.

The recent five year KIMMTRAK overall survival data at AACR 2026 are especially relevant here, because they reinforce the clinical backbone supporting Immunocore’s TCR approach just as brenetafusp moves into a pivotal setting. Together, durable KIMMTRAK outcomes and early brenetafusp signals frame a pipeline story where future data readouts, rather than near term earnings swings, are likely to shape how much value investors ultimately assign to Immunocore.

Yet against this progress, the risk that expanding R&D for three Phase 3 trials strains margins for longer than investors expect is something you should be aware of...

Immunocore Holdings' narrative projects $551.3 million revenue and $88.5 million earnings by 2028.

Uncover how Immunocore Holdings' forecasts yield a $66.57 fair value, a 130% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming Immunocore’s revenue could shrink about 7.5% a year and still reach only around US$327.1 million by 2029, which is a much more pessimistic view than the idea that brenetafusp and other late stage assets could diversify the business, so this new melanoma data may eventually shift how you weigh these very different outlooks.

Explore 3 other fair value estimates on Immunocore Holdings - why the stock might be worth over 8x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Immunocore Holdings research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Immunocore Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunocore Holdings' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.